Overview

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Yuankai Shi
Treatments:
Carboplatin
Etoposide
Ifosfamide